51ºÚÁϳԹÏÍø

ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
51ºÚÁϳԹÏÍø

Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 51ºÚÁϳԹÏÍø Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

51ºÚÁϳԹÏÍø Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Citations : 1089

Indexed In
  • CAS Source Index (CASSI)
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Genamics JournalSeek
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • Publons
  • Euro Pub
  • ICMJE
Share This Page

Surya Ayalasomayajula

DMPK, Novartis Institutes for BioMedical Research (NIBR), East Hanover, NJ, USA

Biography

Dr. Surya Ayalasomayajula is affiliated to Drug Metabolism and Pharmacokinetics, Novartis Institutes for Biomedical Research. Dr. Surya Ayalasomayajula is currently providing services as Professor. Dr. Surya Ayalasomayajula has authored and co-authored multiple peer-reviewed scientific papers and presented works at many national and International conferences. Dr. Surya Ayalasomayajula contributions have acclaimed recognition from honourable subject experts around the world. Dr. Surya Ayalasomayajula is actively associated with different societies and academies. Dr. Surya Ayalasomayajula academic career is decorated with several reputed awards and funding. Dr. Surya Ayalasomayajula research interests include Drug Metabolism and Pharmacokinetics.
Publications

Assessment of Drug Interaction Potential between LCZ696, an Angiotensin Receptor Neprilysin Inhibitor, and Digoxin or Warfa rin

LCZ696 (sacubitril/valsartan) is a first-in-class angiotensin receptor neprilysin inhibitor that simultaneously inhibits neprilysin and blocks the angiotensin II receptor. LCZ696 has been recently approved for treatment of HF and likely be co-administered with digoxin or warfarin. The drug interaction potential between LCZ696 and digoxin or warfari... Read More»

Surya Ayalasomayajula, Pierre Jordaan, Parasar Pal, Priyamvada Chandra, Diego Albrecht, Thomas Langenickel, Iris Rajman and Gangadhar Sunkara

Research Article: Clin Pharmacol Biopharm 2015, 4:147

DOI:

Abstract Peer-reviewed Full Article Peer-reviewed Article PDF

International Conferences 2025-26
 
Meet Inspiring Speakers and Experts at our 3000+ Global

Conferences by Country

Medical & Clinical Conferences

Conferences By Subject

Top